AstraZeneca has confirmed plans to begin Phase II clinical trials of CytoFab for severe sepsis. That's good news for BTG, which acquired CytoFab when it merged with Protherics. "AstraZeneca's continued commitment to CytoFab is a clear positive for BTG, especially considering the investment required for such a high risk indication," said Nomura Code Securities analyst Samir Devani. Report